Baird analyst Michael Ha said the weakness in Oscar Health (OSCR) following ts results is a buying opportunity and he expects the shares to trade back to around $18 in the near-term. Baird reiterated its Outperform rating and $28 price target on Oscar Health shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: